Medigene AG to present at the Baader Investment Conference 2023
September 11, 2023 12:30 ET
|
Medigene AG
Planegg/Martinsried, September 11, 2023. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell...
Medigene AG to present at the H.C. Wainwright 25th Annual Global Investment Conference
September 05, 2023 11:00 ET
|
Medigene AG
Planegg/Martinsried, September 5, 2023. Medigene AG (Medigene, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for...
Medigene presents rationale for combining its 3S TCRs with enhancement tools as an approach to improve clinical outcomes
August 30, 2023 17:00 ET
|
Medigene AG
Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard) is an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors. Prof....
Medigene Expands Intellectual Property Rights for its Costimulatory Switch Proteins to Additional Immune Cell Types
August 23, 2023 08:00 ET
|
Medigene AG
Planegg/Martinsried, August 23, 2023. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell...
Medigene AG to present at the 8th CAR-TCR Summit in Boston
August 22, 2023 10:00 ET
|
Medigene AG
Planegg/Martinsried, August 22, 2023. Medigene AG (Medigene, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for...
Medigene AG Reports Second Quarter and Six Months 2023 Financial Results and Provides Corporate Update
August 17, 2023 02:00 ET
|
Medigene AG
Pipeline expansion into neoantigens with multiple KRAS mutations as the first targets Acquired exclusive, worldwide rights to a CD40L-CD28 costimulatory switch protein Data from MDG1015 and multiple...
Medigene to participate in the H.C. Wainwright Immune Cell Engager Virtual Conference
August 16, 2023 14:30 ET
|
Medigene AG
Planegg/Martinsried, August 16, 2023. Medigene AG (Medigene, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for...
Medigene AG to report Second Quarter and Six Months 2023 Financial Results and Corporate Update on August 17, 2023
August 10, 2023 11:30 ET
|
Medigene AG
Planegg/Martinsried, August 10, 2023. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell...
Medigene Presents Enhanced Tumor Cell Killing Effects upon Addition of PD1-41BB Switch Receptor to TCR-T Therapies
June 22, 2023 12:10 ET
|
Medigene AG
Planegg/Martinsried, 22 June 2023. Medigene AG (Medigene, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid...
Medigene to Present Data Highlighting the Enhanced Tumor Cell Killing Effects of Adding the PD1-41BB Switch Receptor to Multiple TCR-T Therapies at the Immuno-Oncology Summit Europe
June 14, 2023 09:00 ET
|
Medigene AG
Planegg/Martinsried, June 14, 2023. Medigene AG (Medigene, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for...